Does Semaglutide Cause Kidney Stones? A Doctor Explains

Semaglutide has transformed the management of type 2 diabetes and obesity, offering significant benefits in blood sugar control and weight loss. However, like all medications, semaglutide comes with potential side effects, one of which is an increased risk of kidney stones. As a family medicine physician, I frequently field questions from patients about whether semaglutide causes kidney stones, how common this side effect is, and what can be done to manage it. In this article, I’ll break down the evidence, explain the connection between semaglutide and kidney stones, and provide practical guidance for those taking this medication.

Why Does Semaglutide Cause Kidney Stones?

Semaglutide, a GLP-1 receptor agonist, works by mimicking the action of the glucagon-like peptide-1 (GLP-1) hormone, which regulates blood sugar and appetite. While semaglutide is highly effective, its mechanism of action may indirectly contribute to the formation of kidney stones. One of the primary reasons is dehydration. Semaglutide slows gastric emptying, which can lead to reduced fluid intake and increased fluid loss through nausea or decreased thirst. Dehydration is a well-established risk factor for kidney stones, as it concentrates urine and promotes the crystallization of minerals like calcium, oxalate, and uric acid.

Additionally, semaglutide may alter urinary composition. Some studies suggest that GLP-1 receptor agonists like semaglutide can increase urinary calcium excretion, a key component in the formation of calcium-based kidney stones. While the exact mechanism isn’t fully understood, it’s hypothesized that semaglutide may influence renal tubular function or parathyroid hormone levels, both of which play a role in calcium metabolism.

Lastly, rapid weight loss—a common outcome of semaglutide use—has been linked to an increased risk of kidney stones. Weight loss can lead to the release of stored calcium and oxalate from fat tissues, which are then excreted in the urine. This surge in urinary minerals can overwhelm the kidneys’ ability to keep them dissolved, leading to stone formation.

How Common Is Kidney Stones on Semaglutide?

The incidence of kidney stones in patients taking semaglutide is not as well-documented as other semaglutide side effects like nausea or gastrointestinal discomfort. However, clinical trials and post-marketing data provide some insights. In the STEP trials (Semaglutide Treatment Effect in People with Obesity), which evaluated semaglutide for weight loss, kidney stones were reported as an adverse event in a small percentage of participants—roughly 1-2%. For comparison, the general population has a lifetime risk of about 10-15% for developing kidney stones, suggesting that semaglutide may modestly increase this risk.

In patients with type 2 diabetes, the risk of kidney stones is already elevated due to metabolic factors like insulin resistance and obesity. A study published in Diabetes Care found that individuals with diabetes have a 30-50% higher risk of kidney stones compared to those without diabetes. When semaglutide is added to the mix, the risk may climb further, though the exact increase is difficult to quantify due to confounding factors like diet, hydration status, and pre-existing conditions.

It’s also worth noting that kidney stones are more commonly reported in patients taking higher doses of semaglutide (e.g., 2.4 mg for weight loss) compared to lower doses (e.g., 0.5 mg or 1 mg for diabetes). This dose-dependent relationship suggests that the risk may be influenced by the degree of weight loss or metabolic changes induced by semaglutide.

How Long Does Semaglutide Kidney Stones Last?

The duration of kidney stones while taking semaglutide depends on several factors, including the size of the stone, its location, and whether it passes spontaneously or requires medical intervention. For most patients, kidney stones caused by semaglutide are small (less than 5 mm) and pass on their own within 1-2 weeks. However, larger stones (greater than 6 mm) may take longer to pass or may not pass at all without treatment, leading to prolonged discomfort.

The timeline can also be influenced by how long a patient has been taking semaglutide. In the early stages of treatment, when weight loss and metabolic changes are most rapid, the risk of kidney stone formation may be higher. This is because the body is adjusting to shifts in urinary composition and fluid balance. Over time, as the body adapts to semaglutide, the risk of new stone formation may decrease, though it doesn’t disappear entirely.

For patients who experience recurrent kidney stones while on semaglutide, the episodes may persist as long as they remain on the medication. In such cases, preventive measures (e.g., increased hydration, dietary modifications) become critical to managing the condition. If stones continue to form despite these measures, a discussion with a healthcare provider about adjusting the semaglutide dose or exploring alternative treatments may be necessary.

How to Manage Kidney Stones While Taking Semaglutide

Managing kidney stones while on semaglutide requires a multi-faceted approach that addresses hydration, diet, and medication adjustments. The first and most important step is increasing fluid intake. Aim for at least 2.5-3 liters of water daily to dilute urine and reduce the concentration of stone-forming minerals. Patients should monitor their urine color—pale yellow or clear urine indicates adequate hydration, while dark yellow urine suggests dehydration.

Dietary modifications can also play a key role. For calcium oxalate stones, the most common type, reducing oxalate-rich foods (e.g., spinach, nuts, chocolate) and limiting sodium intake can help. However, it’s important not to restrict calcium intake, as this can paradoxically increase the risk of stones. Instead, focus on getting calcium from food sources like dairy or fortified plant-based milks. For uric acid stones, reducing purine-rich foods (e.g., red meat, shellfish) and maintaining a healthy weight can be beneficial.

In some cases, medications may be prescribed to prevent stone formation. Thiazide diuretics, for example, can reduce urinary calcium excretion, while allopurinol may be used for uric acid stones. Patients should discuss these options with their healthcare provider, especially if they have a history of recurrent kidney stones.

Finally, if a kidney stone is causing severe pain or doesn’t pass within a few weeks, medical intervention may be necessary. Options include extracorporeal shock wave lithotripsy (ESWL), which uses sound waves to break up stones, or ureteroscopy, a procedure to remove stones directly from the urinary tract. In rare cases, surgery may be required.

When to See Your Doctor About Semaglutide and Kidney Stones

While many kidney stones pass on their own, there are certain situations where medical attention is necessary. Seek immediate care if you experience any of the following symptoms:

• Severe pain in the back, side, or lower abdomen that doesn’t improve with over-the-counter pain relievers.
• Nausea and vomiting that prevents you from keeping fluids down, increasing the risk of dehydration.
• Blood in the urine (hematuria), which may appear pink, red, or brown.
• Fever or chills, which could indicate a urinary tract infection or kidney infection (pyelonephritis), a serious complication that requires antibiotics.
• Inability to urinate, which may signal a complete blockage of the urinary tract and requires emergency treatment.

Even if your symptoms are mild, it’s important to inform your doctor if you develop kidney stones while taking semaglutide. They may recommend imaging studies (e.g., ultrasound, CT scan) to determine the size and location of the stone and assess whether it’s likely to pass on its own. Your doctor may also evaluate your urinary composition through a 24-hour urine test to identify specific risk factors for stone formation, such as high calcium or oxalate levels.

If you have a history of kidney stones, your doctor may adjust your semaglutide dose or recommend preventive measures before starting treatment. In some cases, they may suggest alternative medications with a lower risk of kidney stones, such as other GLP-1 receptor agonists (e.g., liraglutide) or non-GLP-1 therapies.

Semaglutide Kidney Stones vs Other GLP-1 Side Effects

Kidney stones are just one of many potential side effects associated with semaglutide and other GLP-1 receptor agonists. Compared to more common semaglutide side effects like nausea, vomiting, and diarrhea, kidney stones are relatively rare but can be more serious. Here’s how kidney stones stack up against other GLP-1 side effects:

1. Gastrointestinal (GI) Side Effects: Nausea, vomiting, and diarrhea are the most frequently reported side effects of semaglutide, affecting 30-50% of patients in clinical trials. These symptoms are usually mild to moderate and tend to improve over time as the body adjusts to the medication. Unlike kidney stones, GI side effects are rarely a reason to discontinue semaglutide, though they can contribute to dehydration, which may increase the risk of stones.

2. Hypoglycemia: While semaglutide itself has a low risk of causing low blood sugar, the risk increases when it’s combined with other diabetes medications like sulfonylureas or insulin. Hypoglycemia is more common in patients with type 2 diabetes and can be dangerous if not treated promptly. Unlike kidney stones, hypoglycemia is typically acute and resolves quickly with glucose intake.

3. Pancreatitis: GLP-1 receptor agonists, including semaglutide, have been associated with a slightly increased risk of pancreatitis. Symptoms include severe abdominal pain that radiates to the back, nausea, and vomiting. While rare, pancreatitis is a serious condition that requires immediate medical attention and discontinuation of semaglutide.

4. Gallbladder Disease: Semaglutide may increase the risk of gallstones and gallbladder-related complications, such as cholecystitis. This is thought to be due to rapid weight loss, which can alter bile composition and promote stone formation. Like kidney stones, gallbladder disease is a less common but potentially serious side effect.

5. Thyroid Tumors: In animal studies, semaglutide has been linked to an increased risk of thyroid C-cell tumors. While this risk hasn’t been confirmed in humans, semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Compared to these side effects, kidney stones are less common but can be equally disruptive. The key difference is that kidney stones are often preventable with lifestyle modifications, whereas other GLP-1 side effects may require dose adjustments or medication changes.

Does Semaglutide Dosage Affect Kidney Stones?

The relationship between semaglutide dosage and the risk of kidney stones is not fully understood, but emerging evidence suggests a dose-dependent effect. Higher doses of semaglutide, such as the 2.4 mg weekly dose used for weight loss, are associated with more rapid weight loss and greater metabolic changes, both of which may increase the risk of kidney stones. In contrast, lower doses (e.g., 0.5 mg or 1 mg weekly for diabetes) may carry a lower risk, though kidney stones can still occur.

One reason for this dose-dependent relationship is the impact of semaglutide on urinary calcium excretion. Higher doses of semaglutide may lead to greater increases in urinary calcium, a key factor in the formation of calcium-based kidney stones. Additionally, higher doses are more likely to cause gastrointestinal side effects like nausea and vomiting, which can contribute to dehydration and further elevate the risk of stones.

Patients who start on a lower dose of semaglutide and gradually titrate up may have a lower risk of kidney stones compared to those who start on a higher dose. This is because the body has more time to adapt to the medication’s effects on fluid balance and urinary composition. However, even with gradual dose escalation, the risk of kidney stones persists, particularly in patients with other risk factors like a history of stones or chronic dehydration.

For patients who develop kidney stones while on semaglutide, their doctor may consider lowering the dose or switching to a different GLP-1 receptor agonist with a lower risk of stones. However, this decision must be weighed against the benefits of semaglutide for diabetes or weight management. In some cases, the benefits of continuing semaglutide may outweigh the risks, especially if preventive measures are implemented.

Frequently Asked Questions

Does Semaglutide cause kidney stones in everyone?

No, semaglutide does not cause kidney stones in everyone. While semaglutide may increase the risk of kidney stones, particularly in individuals with other risk factors (e.g., dehydration, history of stones, or rapid weight loss), most patients will not develop this side effect. The overall incidence of kidney stones in clinical trials was low, affecting roughly 1-2% of participants.

How long does kidney stones last on Semaglutide?

The duration of kidney stones while taking semaglutide varies. Small stones (less than 5 mm) typically pass within 1-2 weeks, while larger stones may take longer or require medical intervention. The risk of recurrent stones may persist as long as you’re taking semaglutide, especially if preventive measures like hydration and dietary changes aren’t implemented.

Can you prevent kidney stones on Semaglutide?

Yes, kidney stones on semaglutide can often be prevented with lifestyle modifications. Increasing fluid intake (2.5-3 liters of water daily) is the most effective strategy, as it dilutes urine and reduces the concentration of stone-forming minerals. Dietary changes, such as reducing oxalate or sodium intake, and medications like thiazide diuretics may also help, depending on the type of stone.